This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Background Hypertrophic cardiomyopathy (HCM) is commonly associated with atrialfibrillation (AF), but its impact on outcomes in real-world practice is uncertain. years) were enrolled in the EURObservational Research Programme (EORP) Cardiomyopathy/Myocarditis Registry. Methods Overall, 1739 adult patients with HCM (40.9%
Introduction Catheter ablation is an effective and safe strategy for treating atrialfibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. Among the catheter ablation group, 58.7% ( n = 27) had persistent atrialfibrillation.
When atrialfibrillation (AF) begins, it can start with a single focus, degenerating to multiple wavelets, and it spreads throughout the entire surface area of both atria. A fibrillatory wave that occurs at a rate of more than 600 beats per minute can cause fatigue in the long run, leading to atrial dilation.
Keywords with strong recent citation bursts included tissue, cardiomyopathy, and closed chest ablation.ConclusionPFA is becoming established as a viable alternative for AF ablation, showing promising safety and efficacy. Prolific authors were identified, underscoring significant international collaborations.
Several predictors of atrialfibrillation (AF) onset in patients with hypertrophic cardiomyopathy (HCM) have been proposed, however, all of them showed limited accuracy. This study aims to assess the role of n.
So it must be atrialfibrillation. Answer : it is irregularly irregular and the initial part of the QRS is fast, so this is atrialfibrillation with Left Bundle Branch Block (LBBB). Patient has an ICD, which is primarily placed in patients with cardiomyopathy. What do you think? mm; the S-wave is 18 mm.
Cardiomyopathy frequently contributes to the development of atrialfibrillation (AF). Patients with both AF and cardiomyopathy exhibit higher mortality compared to those with cardiomyopathy alone
Atrialfibrillation (AF) is the most common sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM) and is associated with significant morbiditiy and mortality.
Patients with hypertrophic cardiomyopathy (HCM) undergoing atrialfibrillation (AF) ablation have less favorable outcomes than those without HCM. However, previous studies have limited sample size to assess arrhythmia mechanism and intraprocedural findings during repeat ablation procedures in patients with HCM.
Atrialfibrillation(AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy(HCM). AF in HCM increased the risk of morbidity and mortality and patients with HCM and AF have worse clinical outcomes than those without AF.
Little is known about the distribution and clinical course of patients with genetic arrhythmia syndromes or cardiomyopathy syndromes and concomitant atrialfibrillation (AF).
We thank Hundal and colleagues for their letter1 regarding our analysis of the incidence of new-onset and progressive atrialfibrillation (AF) in mavacamtent-treated patients with obstructive hypertrophic cardiomyopathy (oHCM)2.
Chagas cardiomyopathy (CC) caused by the protozoan Trypanosoma Cruzi results in myocarditis, fibrosis, and chamber dilation; all contributing to an arrhythmogenic substrate that often results in atrialfibrillation (AF). There is currently no consensus on the most appropriate management strategy of AF in CC patients.
male with pertinent past medical history including Atrialfibrillation, atrial flutter, cardiomyopathy, Pulmonary Embolism, and hypertension presented to the Emergency Department via ambulance for respiratory distress and tachycardia. Of course, this is NOT atrial fib, but rather PSVT, and so adenosine should work.
Cardiomyopathy (CM) is associated with arrhythmias, resulting in considerable morbidity and mortality. Atrialfibrillation (AF) is a common arrhythmia linked to adverse outcomes, yet mortality trends between AF and other arrhythmias (OA) in patients with CM remain understudied.
Atrialcardiomyopathy is closely associated with atrialfibrillation (AF), and some patients exhibit no dysfunction at rest but demonstrate evident changes in left atrial (LA) function and LA volume during exe.
Atrialfibrillation (AF) is the most common form of sustained arrhythmia in patients with hypertrophic cardiomyopathy (HCM) and is an important cause of disease-specific morbidity.
Catheter ablation of atrialfibrillation in infiltrative cardiomyopathies ABSTRACT Atrial and ventricular arrhythmias are common in patients with Infiltrative heart diseases. Catheter ablation is a safe and effective modality for the treatment of AF in infiltrative cardiomyopathy.
Oral diuretic intensification was significantly prognostic of mortality amongst patients with transthyretin cardiomyopathy and occurred more often than HF hospitalization. Patients experiencing ODI had higher rates of subsequent mortality (17.7 per 100 person-years; 95% confidence interval [CI] 13.323.7) per 100 person-years; 95% CI 17.750.3)
Percutaneous left atrial appendage closure (LAAC) is an effective alternative strategy for stroke prevention in atrialfibrillation (AF) patients at high risk for bleeding with anticoagulation (AC). Efficacy of this strategy in hypertrophic cardiomyopathy (HCM) remains uncertain.
Atrialfibrillation(AF) is associated with increased risk of embolic stroke and heart failure hospitalizations in patients with hypertrophic cardiomyopathy(HCM).
Advancing age is a well-established risk factor for the development of atrialfibrillation (AF). Atrialfibrillation has previously demonstrated its impact on electrical remodelling of the left atrium (LA). However, less is known about the haemodynamic and functional effects of age.
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. Late-breaking Clinical Trial Results from FARADISE, admIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for AtrialFibrillation Treatment 8.
In this weeks View, Dr. Eagle looks at arrhythmia recurrence and rhythm control after catheter ablation for atrialfibrillation. He then discusses long-term outcomes in transthyretin amyloid cardiomyopathy in patients treated with tafamidis.
Development of a machine learning model to predict new-onset atrialfibrillation in patients with hypertrophic cardiomyopathy. Aims Atrialfibrillation (AF) is the most common sustained arrhythmia among patients with hypertrophic cardiomyopathy (HCM), leading to increased symptom burden and risk of thromboembolism.
study on the frequency of new-onset and recurrent atrialfibrillation (AF) events in patients with obstructive hypertrophic cardiomyopathy (oHCM) on mavacamten.1 We read with interest Castrichini et al.s
BackgroundClinical and genetic predispositions are significant in predicting atrialfibrillation (AF); however, their role in patients with hypertrophic cardiomyopathy (HCM) remains unclear. Journal of the American Heart Association, Ahead of Print.
Atrialfibrillation (AF) is common in patients with hypertrophic cardiomyopathy (HCM) and can be challenging to manage. Atrioventricular nodal (AVN) ablation may be an effective management strategy for AF in these patients.
In patients with hypertrophic cardiomyopathy (HCM), atrialfibrillation (AF) poses significant clinical challenges because of its adverse impact on hemodynamics. AF, especially when accompanied by rapid ventricular responses, compromises atrial contraction and in turn increases diastolic filling of the left ventricle.
The prediction of atrialfibrillation (AF) progression and post-ablation recurrence is currently based on empirical estimates, leading to suboptimal predictive accuracy.
Mavacamten is a cardiac myosin inhibitor that has been shown to reduce left ventricular outflow tract obstruction in obstructive hypertrophic cardiomyopathy (oHCM).1 1 In late-stage clinical trials, atrialfibrillation (AF) represented an adverse event in 2-4 % of the patients randomized to mavacamten.1,2
Increasingly, rare variants in genes encoding sarcomeric proteins like titin (TTN) have been associated with early-onset atrialfibrillation (EOAF) in part by the development of an atrial myopathy.
Common genetic variants associated with atrialfibrillation (AF) may modify the clinical expression of latent ion channel and signaling molecule gene mutations linked with early-onset AF (EOAF). However, the molecular mechanisms by which gene-gene interactions create a substrate for AF is poorly understood.
Wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM) is often accompanied by atrialfibrillation (AF), atrial flutter (AFL), and atrial tachycardia (AT), which are difficult to control because beta-blockers and antiarrhythmic drugs can worsen heart failure (HF).
Long-term follow-up (FU) of the TRED-HF trial: persistent high-risk of relapse following therapy withdrawal in recovered dilated cardiomyopathy (DCM), likely contributed to by low-dose therapy and exposure to external triggers. LVEF, left ventricular ejection fraction. This follow-up investigates the longer-term effects of therapy withdrawal.
Atrialcardiomyopathy (AtCM) associates with atrialfibrillation (AF) and stroke risk. Early, non-invasive identification of AtCM would aid risk-stratification. A new AtCM staging system using ECG, echocardiography and circulating biomarkers was suggested (EHRA/HRS/APHRS/SOLAECE, Goette et al.
Mechanisms and potential targets to manage atrialfibrillation related to diabetes mellitus are represented. ABSTRACT In spite of significant progress made in the management in recent decades, atrialfibrillation (AF) continues to cause increased mortality and significant morbidities, including heart failure and stroke.
Cardiogenic embolism by left atrial thrombi is a significant clinical issue associated with atrialfibrillation (AF). In a previous survey, 91% of AF-related left atrial thrombi was originated in the left atrial appendage (LAA). However, little is known how to evaluate the severity of atrialcardiomyopathy.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
88 
Let's personalize your content